Anti-CD47 antibody- InnobationBio/Thomas Jefferson University

Alternative Names: CD47 immune checkpoint inhibitor; CD47 immune checkpoint inhibitor- Liminatus Pharma/Iris Acquisition Corp

Latest Information Update: 13 Dec 2022

Price : $50 ^*

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator InnobationBio; Thomas Jefferson University
Developer InnobationBio; Liminatus Pharma; Thomas Jefferson University
Class Antibodies; Antineoplastics; Immunotherapies
Mechanism of Action Antibody-dependent cell cytotoxicity; CD47 antigen inhibitors; Macrophage stimulants

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity Yes

05 Dec 2022 Liminatus Pharma collaborates with the Thomas Jefferson University and InnobationBio to co-develop CD47 targeting antibody for cancer
05 Dec 2022 Preclinical trials in Cancer in USA (unspecified route)
05 Dec 2022 Liminatus Pharma announces intention to submit IND to US FDA for Cancer

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com